{"@context":{"@vocab":"https://cir.nii.ac.jp/schema/1.0/","rdfs":"http://www.w3.org/2000/01/rdf-schema#","dc":"http://purl.org/dc/elements/1.1/","dcterms":"http://purl.org/dc/terms/","foaf":"http://xmlns.com/foaf/0.1/","prism":"http://prismstandard.org/namespaces/basic/2.0/","cinii":"http://ci.nii.ac.jp/ns/1.0/","datacite":"https://schema.datacite.org/meta/kernel-4/","ndl":"http://ndl.go.jp/dcndl/terms/","jpcoar":"https://github.com/JPCOAR/schema/blob/master/2.0/"},"@id":"https://cir.nii.ac.jp/crid/1361981471256559616.json","@type":"Article","productIdentifier":[{"identifier":{"@type":"DOI","@value":"10.1016/j.ophtha.2007.02.031"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0161642007003429?httpAccept=text/xml"}},{"identifier":{"@type":"URI","@value":"https://api.elsevier.com/content/article/PII:S0161642007003429?httpAccept=text/plain"}},{"identifier":{"@type":"PMID","@value":"17582498"}}],"dc:title":[{"@value":"One-Year Outcomes of Photodynamic Therapy in Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy in Japanese Patients"}],"description":[{"notation":[{"@value":"To determine the prevalence of polypoidal choroidal vasculopathy (PCV) in Japanese patients presumed to have age-related macular degeneration (AMD) and compare 1-year outcomes after photodynamic therapy between PCV and choroidal neovascularization secondary to AMD.Prospective interventional study.Ninety-three consecutive patients (93 eyes) met the inclusion criteria: at least 50 years old, best-corrected visual acuity (VA) of 34 to 73 on the Early Treatment Diabetic Retinopathy Study (ETDRS) letter chart, a subfoveal lesion 5400 mum or smaller in greatest linear dimension (GLD) on fluorescein angiography (FA), and eligibility for photodynamic therapy.Indocyanine green angiography was performed in all participants, and PCV and AMD were differentiated, treated with photodynamic therapy, and the patients observed for 1 year. The GLD was determined by FA for AMD and by indocyanine green angiography for PCV, and the diameter of the laser spot size was chosen, with an extra 1000 microm added to the GLD. Photodynamic therapy was repeated if leakage occurred on FA at 3-month follow-up visits.Prevalence of PCV at baseline and visual and angiographic changes 1 year after photodynamic therapy in PCV and AMD.Using indocyanine green angiography, 36 eyes (39%) were diagnosed with PCV and 54 eyes (58%) with choroidal neovascularization secondary to AMD. The median change in VA using the ETDRS letter score from baseline to 1 year was -7.0 in AMD eyes and +8.0 in PCV eyes (Mann-Whitney rank sum test; P0.001). The VA improved (or =15 letters) in AMD and PCV by 6% and 25%, respectively, and decreased (or =15 letters) by 31% and 8%, respectively. Fluorescein leakage stopped at 1 year in 86% of PCV and 61% of AMD eyes (P = 0.031). Polypoidal choroidal vasculopathy recurred in 2 PCV eyes (5.6%), and a new PCV lesion developed in 1 PCV eye (2.8%) and 2 AMD eyes (3.7%) on indocyanine green angiography at 1 year.The prevalence of PCV meeting the treatment criteria for photodynamic therapy for presumed AMD is high in Japanese patients. Photodynamic therapy is more efficacious for PCV than for AMD, which may explain the good results in Japanese patients. Further study should assess the long-term clinical results."}]}],"creator":[{"@id":"https://cir.nii.ac.jp/crid/1381981471256559621","@type":"Researcher","foaf:name":[{"@value":"Fumi Gomi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471256559618","@type":"Researcher","foaf:name":[{"@value":"Masahito Ohji"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471256559619","@type":"Researcher","foaf:name":[{"@value":"Kaori Sayanagi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471256559623","@type":"Researcher","foaf:name":[{"@value":"Miki Sawa"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471256559616","@type":"Researcher","foaf:name":[{"@value":"Hirokazu Sakaguchi"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471256559620","@type":"Researcher","foaf:name":[{"@value":"Yusuke Oshima"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471256559617","@type":"Researcher","foaf:name":[{"@value":"Yasushi Ikuno"}]},{"@id":"https://cir.nii.ac.jp/crid/1381981471256559622","@type":"Researcher","foaf:name":[{"@value":"Yasuo Tano"}]}],"publication":{"publicationIdentifier":[{"@type":"PISSN","@value":"01616420"}],"prism:publicationName":[{"@value":"Ophthalmology"}],"dc:publisher":[{"@value":"Elsevier BV"}],"prism:publicationDate":"2008-01","prism:volume":"115","prism:number":"1","prism:startingPage":"141","prism:endingPage":"146"},"reviewed":"false","dc:rights":["https://www.elsevier.com/tdm/userlicense/1.0/","https://www.elsevier.com/legal/tdmrep-license"],"url":[{"@id":"https://api.elsevier.com/content/article/PII:S0161642007003429?httpAccept=text/xml"},{"@id":"https://api.elsevier.com/content/article/PII:S0161642007003429?httpAccept=text/plain"}],"createdAt":"2007-06-21","modifiedAt":"2025-09-27","foaf:topic":[{"@id":"https://cir.nii.ac.jp/all?q=Indocyanine%20Green","dc:title":"Indocyanine Green"},{"@id":"https://cir.nii.ac.jp/all?q=Male","dc:title":"Male"},{"@id":"https://cir.nii.ac.jp/all?q=Porphyrins","dc:title":"Porphyrins"},{"@id":"https://cir.nii.ac.jp/all?q=Visual%20Acuity","dc:title":"Visual Acuity"},{"@id":"https://cir.nii.ac.jp/all?q=Macular%20Degeneration","dc:title":"Macular Degeneration"},{"@id":"https://cir.nii.ac.jp/all?q=Japan","dc:title":"Japan"},{"@id":"https://cir.nii.ac.jp/all?q=Prevalence","dc:title":"Prevalence"},{"@id":"https://cir.nii.ac.jp/all?q=Humans","dc:title":"Humans"},{"@id":"https://cir.nii.ac.jp/all?q=Prospective%20Studies","dc:title":"Prospective Studies"},{"@id":"https://cir.nii.ac.jp/all?q=Fluorescein%20Angiography","dc:title":"Fluorescein Angiography"},{"@id":"https://cir.nii.ac.jp/all?q=Aged","dc:title":"Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Aged,%2080%20and%20over","dc:title":"Aged, 80 and over"},{"@id":"https://cir.nii.ac.jp/all?q=Peripheral%20Vascular%20Diseases","dc:title":"Peripheral Vascular Diseases"},{"@id":"https://cir.nii.ac.jp/all?q=Photosensitizing%20Agents","dc:title":"Photosensitizing Agents"},{"@id":"https://cir.nii.ac.jp/all?q=Choroid","dc:title":"Choroid"},{"@id":"https://cir.nii.ac.jp/all?q=Verteporfin","dc:title":"Verteporfin"},{"@id":"https://cir.nii.ac.jp/all?q=Middle%20Aged","dc:title":"Middle Aged"},{"@id":"https://cir.nii.ac.jp/all?q=Choroidal%20Neovascularization","dc:title":"Choroidal Neovascularization"},{"@id":"https://cir.nii.ac.jp/all?q=Treatment%20Outcome","dc:title":"Treatment Outcome"},{"@id":"https://cir.nii.ac.jp/all?q=Photochemotherapy","dc:title":"Photochemotherapy"},{"@id":"https://cir.nii.ac.jp/all?q=Female","dc:title":"Female"},{"@id":"https://cir.nii.ac.jp/all?q=Follow-Up%20Studies","dc:title":"Follow-Up Studies"}],"relatedProduct":[{"@id":"https://cir.nii.ac.jp/crid/1050012570394383104","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Effectiveness of intravitreal ranibizumab in exudative age-related macular degeneration (AMD): comparison between typical neovascular AMD and polypoidal choroidal vasculopathy over a 1 year follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1050282677154823424","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab."},{"@value":"Clinical investigation: Treatment of polypoidal choroidal vasculopathy by intravitreal injection of bevacizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1050845760656423296","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab."},{"@value":"Treatment of polypoydal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360002216104257664","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"One-Year Results of Intravitreal Aflibercept for Polypoidal Choroidal Vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360004231314169216","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Photodynamic therapy combined with intravitreal bevacizumab and sub-tenon triamcinolone acetonide injections for age-related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360008373650786816","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"One-year outcomes of a treat-and-extend regimen of intravitreal aflibercept for polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360016861598248448","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Macular atrophy at 5 years after photodynamic therapy for polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360023712463587072","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Japanese clinical guidelines for neovascular age-related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360025431114700544","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"The Past, Present, and Future Perspective of Photodynamic Therapy for Age-Related Macular Degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360283692733202816","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"INITIAL VERSUS DELAYED PHOTODYNAMIC THERAPY IN COMBINATION WITH RANIBIZUMAB FOR TREATMENT OF POLYPOIDAL CHOROIDAL VASCULOPATHY"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706291235584","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"A 5-year multicenter prospective cohort study on the long-term visual prognosis and predictive factors for visual outcome in Japanese patients with age-related macular degeneration: the AMD2000 study"}]},{"@id":"https://cir.nii.ac.jp/crid/1360285706926191616","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Efficacy of Intravitreal Bevacizumab Combined With Photodynamic Therapy for Polypoidal Choroidal Vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360294643716621184","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Direct analysis of the actin-filament formation effect in photodynamic therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565165741042816","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Comparison of the Effect of Ranibizumab and Verteporfin for Polypoidal Choroidal Vasculopathy: 12-Month LAPTOP Study Results"}]},{"@id":"https://cir.nii.ac.jp/crid/1360565168459123968","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Three-year visual outcome of photodynamic therapy plus intravitreal bevacizumab with or without subtenon triamcinolone acetonide injections for polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567181902920832","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Polymorphisms in ARMS2 (LOC387715) and LOXL1 Genes in the Japanese With Age-Related Macular Degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567182365080192","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Genetic Variants in Pigment Epithelium-Derived Factor Influence Response of Polypoidal Choroidal Vasculopathy to Photodynamic Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360567185705805056","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Predictable signs of benign course of polypoidal choroidal vasculopathy: based upon the long‐term observation of non‐treated eyes"}]},{"@id":"https://cir.nii.ac.jp/crid/1360584340725303552","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Long-Term Prognosis of Patients with Polypoidal Choroidal Vasculopathy Treated with Photodynamic Therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846640717749248","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Choroidal Thickness Changes After Intravitreal Ranibizumab and Photodynamic Therapy in Recurrent Polypoidal Choroidal Vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360846643901303168","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Responsiveness of eyes with polypoidal choroidal vasculopathy with choroidal hyperpermeability to intravitreal ranibizumab"}]},{"@id":"https://cir.nii.ac.jp/crid/1360848661270106624","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Early Responses to Intravitreal Ranibizumab in Typical Neovascular Age-Related Macular Degeneration and Polypoidal Choroidal Vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1360865815497203840","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Anti-VEGF Treatment Strategies for 3 Subtypes of Neovascular Age-Related Macular Degeneration in a Clinical Setting"}]},{"@id":"https://cir.nii.ac.jp/crid/1390282679973844992","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The New Treatment of Age-Related Macular Degeneration"},{"@value":"加齢黄斑変性の新しい治療"},{"@language":"ja-Kana","@value":"カレイオウハン ヘンセイ ノ アタラシイ チリョウ"}]},{"@id":"https://cir.nii.ac.jp/crid/1390851651021146880","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@language":"en","@value":"The Past and Present of Photodynamic Therapy in Ophthalmology"},{"@language":"ja","@value":"眼科における光線力学的療法（PDT）の歴史と現状"}]},{"@id":"https://cir.nii.ac.jp/crid/1520291854753254272","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CLINICAL INVESTIGATION : Visual outcome of photodynamic therapy for typical neovascular age-related macular degeneration and polypoidal choroidal vasculopathy over 5 years of follow-up"}]},{"@id":"https://cir.nii.ac.jp/crid/1520291855084379520","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Laboratory investigations: Haplotype analysis of the ARMS2/HTRA1 region in Japanese patients with typical neovascular age-related macular degeneration or polypoidal choroidal vasculopathy"},{"@language":"ja-Kana","@value":"Laboratory investigations Haplotype analysis of the ARMS2 HTRA1 region in Japanese patients with typical neovascular age related macular degeneration or polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1521136280304532608","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Effect of combined treatment with sub-Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age-related macular degeneration"},{"@language":"ja-Kana","@value":"Clinical investigation Effect of combined treatment with sub Tenon injection of triamcinolone acetonide and photodynamic therapy in Japanese patients with age related macular degeneration"}]},{"@id":"https://cir.nii.ac.jp/crid/1521136280906377088","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Photodynamic therapy for polypoidal choroidal vasculopathy: baseline perimetric results and visual outcomes"},{"@language":"ja-Kana","@value":"Clinical investigation Photodynamic therapy for polypoidal choroidal vasculopathy baseline perimetric results and visual outcomes"}]},{"@id":"https://cir.nii.ac.jp/crid/1521980705254530816","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Three-year follow-up results of photodynamic therapy for polypoidal choroidal vasculopathy"},{"@language":"ja-Kana","@value":"Clinical investigation Three year follow up results of photodynamic therapy for polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1522262180053820800","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy"},{"@language":"ja-Kana","@value":"Clinical investigation Recurrence of polypoidal choroidal vasculopathy after photodynamic therapy"}]},{"@id":"https://cir.nii.ac.jp/crid/1522543655090957440","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Photodynamic therapy for typical age-related macular degeneration and polypoidal choroidal vasculopathy: a 30-month multicenter study in Hyogo, Japan"},{"@language":"ja-Kana","@value":"Clinical investigation Photodynamic therapy for typical age related macular degeneration and polypoidal choroidal vasculopathy a 30 month multicenter study in Hyogo Japan"}]},{"@id":"https://cir.nii.ac.jp/crid/1522543655342679680","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CLINICAL INVESTIGATION : Effectiveness of polypoidal lesion-selective photodynamic therapy with intravitreal antivascular endothelial growth factor for polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1522543655790057856","@type":"Article","resourceType":"学術雑誌論文(journal article)","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Bevacizumab treatment for choroidal neovascularization due to age-related macular degeneration in Japanese patients"},{"@language":"ja-Kana","@value":"Clinical investigation Bevacizumab treatment for choroidal neovascularization due to age related macular degeneration in Japanese patients"}]},{"@id":"https://cir.nii.ac.jp/crid/1522825130310618496","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy"},{"@language":"ja-Kana","@value":"Clinical investigation Classic choroidal neovascularization developing after photodynamic therapy in eyes with polypoidal choroidal vasculopathy"}]},{"@id":"https://cir.nii.ac.jp/crid/1523669555364359168","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"CLINICAL INVESTIGATION : Treatment results at 1 year of ranibizumab therapy for polypoidal choroidal vasculopathy in eyes with good visual acuity"}]},{"@id":"https://cir.nii.ac.jp/crid/1523951029521101568","@type":"Article","relationType":["isReferencedBy"],"jpcoar:relatedTitle":[{"@value":"Clinical investigation: Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy"},{"@language":"ja-Kana","@value":"Clinical investigation Bevacizumab for serous changes originating from a persistent branching vascular network following photodynamic therapy for polypoidal choroidal vasculopathy"}]}],"dataSourceIdentifier":[{"@type":"CROSSREF","@value":"10.1016/j.ophtha.2007.02.031"},{"@type":"OPENAIRE","@value":"doi_dedup___::5acebb7dcdf5ba442d77796985ceabb2"},{"@type":"CROSSREF","@value":"10.1007/s10384-009-0775-3_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-012-0206-8_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1186/1471-2415-13-10_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.ajo.2010.02.008_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-011-0006-6_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-016-0492-7_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1038/s41433-022-02067-6_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-025-01240-0_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.3390/jcm14041240_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-013-0237-9_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-017-0554-5_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.2530/jslsm.jslsm-42_0016_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1039/d1ra09291j_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1136/bjophthalmol-2014-305189_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-010-0813-1_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1111/j.1755-3768.2009.01850.x_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.ophtha.2015.05.024_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.ophtha.2010.12.011_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.3390/jcm12144707_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1186/1471-2415-13-43_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1155/2011/742020_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.ajo.2011.07.001_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.5363/tits.15.7_33_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-013-0245-9_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.oret.2023.06.002_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.ajo.2013.05.024_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.ajo.2010.08.048_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1097/iae.0000000000000526_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-010-0865-2_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-009-0741-0_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1016/j.ajo.2013.03.041_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-020-00734-3_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-009-0732-1_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-011-0045-z_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-010-0886-x_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-008-0582-2_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"},{"@type":"CROSSREF","@value":"10.1007/s10384-009-0703-6_references_DOI_2Jp71wNbbNfeQq0vrLusJA8epzp"}]}